BRPI0922021A2 - método para avaliar a condição renal em um indivíduo, e, uso de um ou mais marcadores de lesão renal - Google Patents

método para avaliar a condição renal em um indivíduo, e, uso de um ou mais marcadores de lesão renal

Info

Publication number
BRPI0922021A2
BRPI0922021A2 BRPI0922021A BRPI0922021A BRPI0922021A2 BR PI0922021 A2 BRPI0922021 A2 BR PI0922021A2 BR PI0922021 A BRPI0922021 A BR PI0922021A BR PI0922021 A BRPI0922021 A BR PI0922021A BR PI0922021 A2 BRPI0922021 A2 BR PI0922021A2
Authority
BR
Brazil
Prior art keywords
kidney
markers
individual
assessing
condition
Prior art date
Application number
BRPI0922021A
Other languages
English (en)
Inventor
Gray Jeff
Anderberg Joseph
Nakamura Kevin
Mcpherson Paul
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Publication of BRPI0922021A2 publication Critical patent/BRPI0922021A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5434—IL-12
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5446—IL-16
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/55—IL-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Evolutionary Biology (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Evolutionary Computation (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Software Systems (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Signal Processing (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BRPI0922021A 2008-11-10 2009-11-10 método para avaliar a condição renal em um indivíduo, e, uso de um ou mais marcadores de lesão renal BRPI0922021A2 (pt)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US11307408P 2008-11-10 2008-11-10
US11504908P 2008-11-15 2008-11-15
US11716208P 2008-11-22 2008-11-22
US11717808P 2008-11-22 2008-11-22
US11716008P 2008-11-22 2008-11-22
US11715808P 2008-11-22 2008-11-22
US11716808P 2008-11-22 2008-11-22
US11715108P 2008-11-22 2008-11-22
US11716308P 2008-11-22 2008-11-22
US11718008P 2008-11-22 2008-11-22
US11716108P 2008-11-22 2008-11-22
PCT/US2009/063906 WO2010054389A1 (en) 2008-11-10 2009-11-10 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (1)

Publication Number Publication Date
BRPI0922021A2 true BRPI0922021A2 (pt) 2019-09-24

Family

ID=42153314

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922021A BRPI0922021A2 (pt) 2008-11-10 2009-11-10 método para avaliar a condição renal em um indivíduo, e, uso de um ou mais marcadores de lesão renal

Country Status (11)

Country Link
US (3) US8993250B2 (pt)
EP (2) EP2361018B1 (pt)
JP (1) JP5752600B2 (pt)
KR (1) KR20110084286A (pt)
CN (2) CN102264230B (pt)
AU (1) AU2009313189B2 (pt)
BR (1) BRPI0922021A2 (pt)
CA (1) CA2742113A1 (pt)
MX (1) MX2011004767A (pt)
NZ (1) NZ592488A (pt)
WO (1) WO2010054389A1 (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180090396A (ko) 2008-01-18 2018-08-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 체액 내에서 질병 또는 병태의 시그너쳐의 검출 방법
EP2261660B1 (en) * 2008-02-29 2013-08-07 National University Corporation Nagoya University Biomarker for the estimation of acute renal disorder and prognosis of the disorder, and use of the biomarker
BRPI0917711A2 (pt) 2008-08-28 2017-06-20 Astute Medical Inc método para avaliar o estado renal em um paciente, e, uso de um ou mais marcadores de lesão renal
EP2324354B1 (en) 2008-08-29 2014-07-16 Astute Medical, Inc. Methods for prognosis of acute renal failure
CN104391115B (zh) 2008-10-21 2017-04-19 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
BRPI0922021A2 (pt) 2008-11-10 2019-09-24 Astute Medical Inc método para avaliar a condição renal em um indivíduo, e, uso de um ou mais marcadores de lesão renal
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5827226B2 (ja) 2009-08-07 2015-12-02 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
MX340078B (es) 2009-11-07 2016-06-24 Astute Medical Inc Metodos y composiciones para el diagnostico y pronostico de daño renal y falla renal.
KR20120123056A (ko) 2009-12-20 2012-11-07 아스튜트 메디컬 인코포레이티드 신손상 및 신부전을 진단 및 예측하는 방법 및 조성물
EP2531620B1 (en) 2010-02-05 2016-12-14 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2539712A4 (en) 2010-02-26 2013-09-18 Astute Medical Inc METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
AU2011269847A1 (en) 2010-02-26 2013-01-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2585827A4 (en) 2010-06-23 2013-12-04 Astute Medical Inc METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECASTING kidney injury and kidney insufficiency
MX2013000220A (es) * 2010-06-23 2013-03-22 Astute Medical Inc Metodos y composiciones para diagnóstico y pronóstico de lesión renal e insuficiencia renal.
CA2806296A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting kidney-associated diseases or conditions
MX382244B (es) 2010-07-23 2025-03-13 Harvard College Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales
AU2011280944A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting diseases or conditions using phagocytic cells
AU2011280936A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
WO2012094657A1 (en) * 2011-01-08 2012-07-12 Astute Medical, Inc. Method and compositions for diagnosis and prognosis of renal injury and renal failure
AU2012282917A1 (en) * 2011-07-09 2014-01-30 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
TR201903235T4 (tr) * 2011-08-26 2019-03-21 Astute Medical Inc Böbrek hasari ve böbrek yetmezli̇ği̇ni̇n tanilanmasi ve prognozuna yöneli̇k metotlar ve bi̇leşi̇mler.
WO2013086359A1 (en) 2011-12-08 2013-06-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2013096740A1 (en) * 2011-12-21 2013-06-27 Alere San Diego Inc. Methods and compositions for assigning likelihood of chronic kidney disease progression
CN102659937B (zh) * 2012-03-16 2014-01-08 杭州贤至生物科技有限公司 一种重组蛋白及其单克隆抗体的制备方法和应用
US9963885B2 (en) 2012-09-27 2018-05-08 Max Life, LLC Wall panel
US9353523B2 (en) 2012-09-27 2016-05-31 Max Life, LLC Insulated wall panel
US20150309052A1 (en) * 2012-12-20 2015-10-29 Frank Dieterle Acute kidney injury
ES2681955T3 (es) 2013-01-17 2018-09-17 Astute Medical, Inc. Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
NZ771629A (en) 2013-03-09 2022-12-23 Harry Stylli Methods of detecting cancer
EP2965086A4 (en) 2013-03-09 2017-02-08 Harry Stylli Methods of detecting prostate cancer
CN104569417B (zh) * 2013-10-12 2016-06-01 广州瑞博奥生物科技有限公司 一种用于早期诊断急性肾损伤的抗体芯片试剂盒
CN105917229B (zh) 2013-12-03 2019-04-26 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
US9652770B1 (en) 2014-04-30 2017-05-16 Wells Fargo Bank, N.A. Mobile wallet using tokenized card systems and methods
US11288660B1 (en) 2014-04-30 2022-03-29 Wells Fargo Bank, N.A. Mobile wallet account balance systems and methods
US11461766B1 (en) * 2014-04-30 2022-10-04 Wells Fargo Bank, N.A. Mobile wallet using tokenized card systems and methods
US11610197B1 (en) 2014-04-30 2023-03-21 Wells Fargo Bank, N.A. Mobile wallet rewards redemption systems and methods
US10445739B1 (en) 2014-08-14 2019-10-15 Wells Fargo Bank, N.A. Use limitations for secondary users of financial accounts
WO2016040843A1 (en) 2014-09-11 2016-03-17 Harry Stylli Methods of detecting prostate cancer
CN104267187A (zh) * 2014-10-15 2015-01-07 吉林大学 检测尿液Clusterin含量试纸条的制备及应用
HRP20220225T1 (hr) * 2014-10-24 2022-04-29 Mallinckrodt Pharmaceuticals Ireland Limited Terlipresin za liječenje hepatorenalnog sindroma tip 1
ES2943579T3 (es) 2014-12-18 2023-06-14 Astute Medical Inc Procedimientos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
WO2016164854A1 (en) 2015-04-09 2016-10-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR102462056B1 (ko) * 2015-04-30 2022-11-02 아이덱스 래보러토리즈, 인코포레이티드 클루스테린 아이소폼의 특이적 검출
AU2017277305A1 (en) 2016-06-06 2018-12-20 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
WO2018117011A1 (ja) 2016-12-19 2018-06-28 国立大学法人大阪大学 インビトロでのＩｇＭ型メモリーＢ細胞分化培養系を用いた臓器移植後抗体関連型拒絶反応の早期診断法
US11346846B2 (en) 2017-02-06 2022-05-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20180322956A1 (en) 2017-05-05 2018-11-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Time Window-Based Platform for the Rapid Stratification of Blunt Trauma Patients into Distinct Outcome Cohorts
GB201804648D0 (en) * 2018-03-22 2018-05-09 Randox Laboratories Ltd Combination biomarker
WO2019227055A1 (en) 2018-05-24 2019-11-28 Renibus Therapeutics, Inc. Methods of treating patients at risk for renal injury and renal failure
US12045809B1 (en) 2018-08-30 2024-07-23 Wells Fargo Bank, N.A. Biller consortium enrollment and transaction management engine
US12254463B1 (en) 2018-08-30 2025-03-18 Wells Fargo Bank, N.A. Biller directory and payments engine architecture
CN113178243A (zh) * 2021-04-26 2021-07-27 南京医科大学 体外循环心脏手术后急性肾损伤早期预警方法及系统
US12229735B1 (en) 2021-08-17 2025-02-18 Wells Fargo Bank, N.A. Multi-modal parameterization of digital tokens involving multiple entities in defined networks
US11995621B1 (en) 2021-10-22 2024-05-28 Wells Fargo Bank, N.A. Systems and methods for native, non-native, and hybrid registration and use of tags for real-time services
GB202206257D0 (en) * 2022-04-29 2022-06-15 Randox Laboratories Ltd Biomarkers of diabetic nephropathy
GB202208742D0 (en) * 2022-06-14 2022-07-27 Tintra 3 0 Ltd Authentication and association of multi-platform accounts and method of obfuscating senstive personal data in processes requiring personal identification
CN121186383B (zh) * 2025-11-24 2026-03-13 华中科技大学 慢性肾病的蛋白质标志物的筛选及应用

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1429031A1 (ru) 1986-06-20 1988-10-07 Калининский Государственный Медицинский Институт Способ дифференциальной диагностики гломерулонефрита и пиелонефрита
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
JPH05504841A (ja) 1990-09-14 1993-07-22 バイオサイト・ダイアグノスティックス・インコーポレイテッド リガンドレセプター及びリガンドのコンプレックスに対する抗体及びリガンド―レセプターアッセーでのそれらの用途
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
WO1992018868A1 (en) 1991-04-10 1992-10-29 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
ATE195808T1 (de) 1991-04-12 2000-09-15 Biosite Diagnostics Inc Neue konjugate und testverfahren für die gleichzeitige bestimmung von multiplen liganden
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
SK285461B6 (sk) 1996-05-24 2007-02-01 Biogen Idec Ma Inc. Izolovaný polypeptid KIM, modulátor tkanivovej regenerácie a nukleová kyselina, ktorá ho kóduje, spôsob prípravy polypeptidu a farmaceutická kompozícia obsahujúca polypeptid
US5753455A (en) 1996-09-03 1998-05-19 Bayer Corporation Method for the detection of lysozyme using a protein error indicator dye in conjunction with an alkane sulfonic acid
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
WO1998055508A2 (en) 1997-06-03 1998-12-10 Sagami Chemical Research Center HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS
US20060223077A1 (en) 1997-06-06 2006-10-05 Human Genome Sciences, Inc. 207 human secreted proteins
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
BR9916407A (pt) 1998-12-21 2001-09-25 Univ Monash Detecção e tratamento de doenças dos rins
RU2180965C1 (ru) 2000-07-03 2002-03-27 Габбасова Наталья Вадимовна Способ дифференциальной диагностики заболеваний почек
WO2002054081A2 (en) 2000-12-29 2002-07-11 Oxford Glycosciences (Uk) Limited Proteins, genes and their use for diagnosis and treatment of kidney response
US20060088823A1 (en) 2001-03-29 2006-04-27 Brian Haab Microarray gene expression profiling in clear cell renal cell carcinoma : prognosis and drug target identification
US20070015146A1 (en) 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US20030003588A1 (en) 2001-06-28 2003-01-02 Comper Wayne D. Method for kidney disease detection by protein profiling
CA2454342A1 (en) 2001-07-24 2003-02-06 Yale University Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease
US6784154B2 (en) 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
US8404229B2 (en) 2001-12-07 2013-03-26 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to treat acute tubular necrosis
GB0130557D0 (en) 2001-12-20 2002-02-06 Serono Internat S A Proteins
WO2003075016A1 (en) 2002-03-07 2003-09-12 Cambridge University Technical Services Limited (Cuts) Scd fingerprints
EP1532268A4 (en) 2002-03-21 2006-07-05 Yissum Res Dev Co PERIPHERAL BLOOD CELL MARKERS SUITABLE FOR THE DIAGNOSIS OF MULTIPLE SCLEROSIS AND THESE USEFUL METHODS AND KITS
CN1376923A (zh) * 2002-04-08 2002-10-30 刘友华 肝细胞生长因子的测定方法
US7138230B2 (en) 2002-12-06 2006-11-21 Renovar, Inc. Systems and methods for characterizing kidney diseases
US7138229B2 (en) 2002-12-06 2006-11-21 Renovar, Inc. Systems and methods for characterizing kidney diseases
GB0215509D0 (en) * 2002-07-04 2002-08-14 Novartis Ag Marker genes
AU2003281287A1 (en) * 2002-07-04 2004-01-23 Oxford Glycosciences (Uk) Ltd Toxicity markers
US6941172B2 (en) 2002-11-18 2005-09-06 Zvi Nachum Method and device for restoring kidney function using electromagnetic stimulation
US20060063156A1 (en) 2002-12-06 2006-03-23 Willman Cheryl L Outcome prediction and risk classification in childhood leukemia
CN1791797A (zh) 2003-03-27 2006-06-21 儿童医院医疗中心 用于检测肾小管细胞损伤的早发的方法和试剂盒
EP1613273B1 (en) 2003-04-11 2012-06-13 MedImmune, LLC Recombinant il-9 antibodies and uses thereof
WO2005002416A2 (en) 2003-06-04 2005-01-13 Joslin Diabetes Center, Inc. Predictors of renal disease
US20050148029A1 (en) 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
DE602004019134D1 (de) 2003-09-29 2009-03-05 Peas Inst Ab Schnelle bestimmung verschiedener formen von hgf (heptocyte growth factor) in den körperflüssigkeiten
GB0329288D0 (en) 2003-12-18 2004-01-21 Inverness Medical Switzerland Monitoring method and apparatus
EP1727564A1 (en) 2004-03-17 2006-12-06 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Cd44-targeting for reducing/preventing ischemia-reperfusion-injury
WO2005103281A2 (en) 2004-04-26 2005-11-03 Children's Medical Center Corporation Platelet biomarkers for the detection of disease
US20050272101A1 (en) 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
US7588892B2 (en) 2004-07-19 2009-09-15 Entelos, Inc. Reagent sets and gene signatures for renal tubule injury
US20080038192A1 (en) 2004-07-19 2008-02-14 Neurochem Inc. Diagnostic Methods Of Multiple Organ Amyloidosis
US7141382B1 (en) 2004-10-12 2006-11-28 Parikh Chirag R Methods for detection of IL-18 as an early marker for diagnosis of acute renal failure and predictor of mortality
US20090258002A1 (en) 2005-02-01 2009-10-15 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for Tissue Status
EP2604703B1 (en) 2005-03-14 2017-02-01 The Board of Trustees of the Leland Stanford Junior University Methods for evaluating graft survival in a solid organ transplant recipient
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
US20070037232A1 (en) 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
SG2014011837A (en) 2005-04-18 2014-04-28 Mitomics Inc Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
US20070087387A1 (en) 2005-04-21 2007-04-19 Prasad Devarajan Method for the Early Detection of Renal Disease Using Proteomics
US7833732B2 (en) 2005-07-21 2010-11-16 The John Hopkins University Acute renal injury
US7759077B2 (en) 2005-08-02 2010-07-20 Shariat Shahrokh F Soluble fas urinary marker for the detection of bladder transitional cell carcinoma
EP1757940A1 (en) 2005-08-26 2007-02-28 Cézanne S.A.S. In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC
JP2009510478A (ja) 2005-10-03 2009-03-12 バイオサイト インコーポレイテッド 全身性炎症反応症候群の診断および／または予後診断のための方法および組成物
US20080090304A1 (en) 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
US8329408B2 (en) 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
US10716749B2 (en) 2005-11-03 2020-07-21 Palo Alto Investors Methods and compositions for treating a renal disease condition in a subject
US20080133141A1 (en) 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
TW200726845A (en) 2006-01-02 2007-07-16 Nat Defense Medical Ct Biomarker molecular of renal illness and detecting method for the same
GB0605217D0 (en) 2006-03-15 2006-04-26 Novartis Ag Method and compositions for assessing acute rejection
GB0606776D0 (en) 2006-04-03 2006-05-10 Novartis Pharma Ag Predictive biomarkers for chronic allograft nephropathy
US7662578B2 (en) 2006-04-21 2010-02-16 Children's Hospital Medical Center Method and kit for the early detection of impaired renal status
US20080038269A1 (en) * 2006-05-25 2008-02-14 Mount Sinai Hospital Methods for detecting and treating kidney disease
WO2008084331A2 (en) 2006-06-21 2008-07-17 Hopitaux Universitaires De Geneve Biomarkers for renal disorders
WO2008005375A2 (en) 2006-06-30 2008-01-10 Merck & Co., Inc. Kidney toxicity biomarkers
EP2049713A4 (en) 2006-07-21 2010-06-16 Univ Alberta tissue rejection
GB0617429D0 (en) 2006-09-05 2006-10-18 Electrophoretics Ltd Markers of renal transplant rejection and renal damage
US20080206794A1 (en) 2006-09-15 2008-08-28 Renovar Incorporated Systems And Methods For Characterizing Contrast Induced-Nephropathy
WO2008060607A2 (en) 2006-11-14 2008-05-22 Biosite Incorporated Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
WO2008073899A2 (en) 2006-12-08 2008-06-19 The Children's Hospital Of Philadelphia Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
GB0701626D0 (en) 2007-01-22 2007-03-07 Cambridge Entpr Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
ES2532221T3 (es) 2007-03-26 2015-03-25 Novartis Ag Biomarcadores de seguridad renal predictiva y señales de biomarcadores para monitorizar la función renal
CA2682538A1 (en) 2007-04-10 2008-10-16 Integragen Human diabetes susceptibility tnfrsf10b gene
US8080394B2 (en) 2007-04-27 2011-12-20 Brigham And Women's Hospital Method for determining predisposition to pulmonary infection
US9091695B2 (en) 2007-06-01 2015-07-28 Laboratory Corporation Of America Holdings Methods and systems for quantification of peptides and other analytes
US20100184110A1 (en) 2007-06-06 2010-07-22 Siemens Healthcare Diagnostics Inc. Predictive diagnostics for kidney disease
US20090047689A1 (en) 2007-06-20 2009-02-19 John Kolman Autoantigen biomarkers for early diagnosis of lung adenocarcinoma
US20100267041A1 (en) 2007-09-14 2010-10-21 Predictive Biosciences, Inc. Serial analysis of biomarkers for disease diagnosis
WO2009038742A2 (en) 2007-09-20 2009-03-26 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for estimating risk of acute kidney injury
WO2009039421A1 (en) 2007-09-20 2009-03-26 University Of Louisville Research Foundation, Inc. Peptide biomarkers predictive of renal function decline and kidney disease
US8003333B2 (en) 2007-09-28 2011-08-23 Mayo Foundation For Medical Education And Research Serum biomarkers for early detection of acute cellular rejection
EP2261660B1 (en) 2008-02-29 2013-08-07 National University Corporation Nagoya University Biomarker for the estimation of acute renal disorder and prognosis of the disorder, and use of the biomarker
US20090298106A1 (en) 2008-05-30 2009-12-03 Therapeutic Monitoring Services, L.L.C. Methods for Monitoring Immunosuppressant Drug Levels, Renal Function, and Hepatic Function Using Small Volume Samples
US8241861B1 (en) 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
EP2149613A1 (en) 2008-07-28 2010-02-03 Greenwood Genetic Center, Inc. Methods for determining dysregulation of methylation of brain expressed genes on the X chromosome to diagnose autism spectrum disorders
US8673574B2 (en) 2008-08-21 2014-03-18 Pxbiosciences Llc Diagnosis and monitoring of renal failure using peptide biomarkers
BRPI0917711A2 (pt) 2008-08-28 2017-06-20 Astute Medical Inc método para avaliar o estado renal em um paciente, e, uso de um ou mais marcadores de lesão renal
EP2324354B1 (en) 2008-08-29 2014-07-16 Astute Medical, Inc. Methods for prognosis of acute renal failure
US8501489B2 (en) 2008-09-26 2013-08-06 University of Pittsburgh—of the Commonwealth System of Higher Education Urinary biomarkers to predict long-term dialysis
NZ619918A (en) 2008-10-21 2015-04-24 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN104391115B (zh) 2008-10-21 2017-04-19 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
BRPI0922021A2 (pt) 2008-11-10 2019-09-24 Astute Medical Inc método para avaliar a condição renal em um indivíduo, e, uso de um ou mais marcadores de lesão renal
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20120053072A1 (en) 2009-02-06 2012-03-01 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010111746A1 (en) 2009-04-03 2010-10-07 Vegenics Limited Anti-vegf-d antibodies
EP2427494B1 (en) 2009-05-08 2017-10-18 Novartis AG Methods of modulating fibrosis using bone morphogenetic protein-9 (bmp-9) modulators
WO2011017685A1 (en) 2009-08-07 2011-02-10 Rules-Based Medicine, Inc. Methods and devices for detecting kidney transplant rejection
NZ630277A (en) 2009-09-21 2015-02-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR20120123056A (ko) 2009-12-20 2012-11-07 아스튜트 메디컬 인코포레이티드 신손상 및 신부전을 진단 및 예측하는 방법 및 조성물
US20130035290A1 (en) 2011-05-17 2013-02-07 Yale University Chitinase-3-Like Protein 1 as a Biomarker of Recovery from Kidney Injury

Also Published As

Publication number Publication date
CN102264230B (zh) 2014-12-10
MX2011004767A (es) 2011-09-06
NZ592488A (en) 2012-10-26
WO2010054389A1 (en) 2010-05-14
US20160054336A1 (en) 2016-02-25
KR20110084286A (ko) 2011-07-21
EP2913676A1 (en) 2015-09-02
CA2742113A1 (en) 2010-05-14
US8993250B2 (en) 2015-03-31
AU2009313189B2 (en) 2014-10-23
JP5752600B2 (ja) 2015-07-22
US9470695B2 (en) 2016-10-18
CN104330574B (zh) 2017-04-12
JP2012508382A (ja) 2012-04-05
US20170030927A1 (en) 2017-02-02
EP2361018A1 (en) 2011-08-31
CN102264230A (zh) 2011-11-30
AU2009313189A1 (en) 2010-05-14
EP2361018A4 (en) 2012-07-11
EP2361018B1 (en) 2015-04-01
HK1203619A1 (en) 2015-10-30
CN104330574A (zh) 2015-02-04
HK1162121A1 (en) 2012-08-24
US20110306063A1 (en) 2011-12-15

Similar Documents

Publication Publication Date Title
BRPI0922021A2 (pt) método para avaliar a condição renal em um indivíduo, e, uso de um ou mais marcadores de lesão renal
BRPI0919640A2 (pt) método para avaliar a situação renal em um indivíduo, e, uso de um ou mais marcadores de lesão renal
BRPI0921921A2 (pt) método para avaliar a condição renal em um indivíduo, e, uso de um ou mais marcadores de lesão renal.
BRPI0917711A2 (pt) método para avaliar o estado renal em um paciente, e, uso de um ou mais marcadores de lesão renal
BRPI1007917A2 (pt) método para avaliar a situação renal em um indivíduo, e, uso de um ou mais marcadores de lesão renal
BRPI0816349A2 (pt) sistema, sistema para uso em um poço, e método
BRPI0914007A2 (pt) anatagonistas e agentes de ligação de notch e métodos para uso dos mesmos
BRPI0909002A2 (pt) aparelho para uso em um poço, sistema, e método para uso em um poço
BRPI0921579A2 (pt) método para ligar dinamicamente programa em plataforma embutida e plataforma embutida
BRPI0820148A2 (pt) Sistema de aberturas, sistema de computador e método para usinar aberturas
BRPI0720695A2 (pt) Compostos e métodos para modulação de cinase, e indicações para estes
BRPI0821781A2 (pt) Sistemas e métodos para localizar um dispositivo móvel.
BRPI0813216A2 (pt) Inibidores de proteínas cinases e métodos para usá-los.
BRPI0818056A2 (pt) Aparelho e métodos para hemodiálise
BRPI0906772A2 (pt) Método e equipamento para utilizar informações de capacidade de serviço para localização em plano de usuário
BRPI0821452A2 (pt) Método para processar um ou mais hidrocarbonetos, e, sistema para processar hidrocarbonetos
BRPI0910608A2 (pt) métodos e sistemas para avaliar resultados clínicos
ES2455669T8 (es) Método, dispositivo y sistema para identificar un equipo de usuario
BRPI0912426A2 (pt) método executado por computador, computador, e sistema para uso com poço
BRPI0716152A2 (pt) sistemas, mÉtodos, software e interfaces para formatar citaÇÕes legais
BRPI1015922A2 (pt) sistemas e métodos para testar analitos
BRPI0718974A2 (pt) Copolímero, e, método para preparar um copolímero
BRPI0807476A2 (pt) Aparelho eletrônico, e, método de detecção de laço para uso em um aparelho eletrônico.
BR112012013247A2 (pt) conjunto submarino e método para uso em operações submarinas"
BRPI0821477A2 (pt) método para processar um ou mais hidrocarbonetos, e, sistema para processar hidrocarbonetos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.